TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05100251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBC100 QOD
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 7 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QOD. The second dose group is 1mg QOD. The third dose group is 1.5 mg QOD. The fourth dose group is 2.0 mg QOD. The fifth dose group is 2.5 mg QOD. The sixth dose group is 3.0 mg QOD. The seven dose group is 3.5 mg QOD. In each dose group, patients take WBC100 once on cycle 0. After a washout period of 2 days, patents start subsequent 4 weeks cycles until progression disease or intolerable toxicity. In each cycle, patient was on WBC100 every for 3 weeks and off for 1 week.~The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBC100 QD
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 6 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. The fifth dose group is 2.5 mg QD. The sixth dose group is 3.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for for 3 consecutive weeks (with QD dosing for the first 5 days of each week followed by a 2-day rest), followed by a 1-week rest period, with a 4 weeks as one cycle. The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WBC100 BID
Description: The first stage: single dose escalation according to classic 3+3 dose escalation method. 4 increasing dose levels were set up, with 3 to 6 cases per dose. The first dose group is 0.5 mg QD. The second dose group is 1mg QD. The third dose group is 1.5 mg QD. The fourth dose group is 2.0 mg QD. In each dose group, the patient was on WBC100 until progression disease or intolerable toxicity. Patient was on WBC100 every for 2 consecutive weeks, followed by a 1-week rest period, with 3 weeks as one treatment cycle; The second stage: Two dose levels will be chosen according to data from the first stage. Each dose stage will enroll 12 c-myc-positive patients with a selected cancer type
Study: NCT05583877

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual care for DSMT.
Study: NCT06484985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT-1003
Description: AXT-1003 capsule is administered orally daily, until disease progression or intolerable toxicity.
Study: NCT05368558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cariprazine
Description: Oral Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Capsule
Study: NCT05070390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Chloride
Description: 10 mg capsule administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Chloride
Description: 10 mg capsule administered orally
Study: NCT06285240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: 1 mg and 5 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1167
Description: 1 mg and 5 mg oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 10 mg oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 10 mg oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-1167 matching placebo administered oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MK-1167 matching placebo administered oral capsules
Study: NCT05287399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC61 200 mg 1
Description: 200mg of ASC61 orally once daily for cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC61 200 mg 2
Description: 200 mg of ASC61 orally twice daily for cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC61 300 mg
Description: 300 mg of ASC61 orally twice daily for cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC61 400 mg
Description: 400 mg of ASC61 orally twice daily for cycles of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC61 600 mg
Description: 600 mg of ASC61 orally twice daily for cycles of 28 days
Study: NCT05254158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174 0833
Description: Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174 0833
Description: Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174 0833
Description: Participants will either get a single dose of 0.3 mg, 0.9 mg or 1.8 mg NNC0174-0833, administered subcutaneously (s.c., under the skin)
Study: NCT04766229

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Citalopram +/- Gabapentin + Sleepio + support person
Description: All participants will receive citalopram and/or gabapentin to manage vasomotor symptoms of menopause and will get access to digital CBT for insomnia and be asked to identify a support person
Study: NCT05618028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-525
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-525
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-525
Description: Oral; Tablet
Study: NCT05534971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheter insertion
Description: The clinical team will use the technique to establish central venous access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central venous catheter insertion
Description: The clinical team will use the technique to establish central venous access
Study: NCT04720508

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection.
Description: venipuncture procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample collection.
Description: venipuncture procedure
Study: NCT04835805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belvarafenib
Description: Twice daily (BID), continuous dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off
Study: NCT06512441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B6 Tablets
Description: The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B6 Tablets
Description: The experimental group was given a Vitamin B6 tablet（10mg/tablet）once a day for 3weeks, besides of the standard IBD treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group was given a placebo tablet on the same type once a day for 3weeks, besides of the standard IBD treatment.
Study: NCT06381518

Intervention type: OTHER
Group type: OTHER
Intervention: Switch to SC CT-P13.
Description: all patients in the study will switch from IFX to SC CT-P13

Intervention type: OTHER
Group type: OTHER
Intervention: Switch to SC CT-P13.
Description: all patients in the study will switch from IFX to SC CT-P13
Study: NCT05804305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a prostaglandin E1 analogue

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contained substance that has no therapeutic value.
Study: NCT04835805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Once every 4 weeks (Q4W)
Study: NCT04802967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen Lysine Salt combined with Gabapentin
Description: KLS-GABA (80 mg-34 mg) in Part A and KLS-GABA (40 mg-17 mg or 80 mg-34 mg or 160 mg-68 mg) in Part B

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoprofen Lysine Salt
Description: KLS (80 mg) alone in each treatment period in Part A and KLS alone (40 mg, 80 mg, or 160 mg) in Part B
Study: NCT06560632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3467 at assigned dose and schedule
Description: Eligible participants will be treated with escalating doses of RP-3467 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-3467 at assigned dose and schedule
Description: Eligible participants will be treated with escalating doses of RP-3467 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 200-300 mg BID, daily
Description: Eligible participants will be treated with escalating doses of RP-3467 in combination with Olaparib
Study: NCT04514497

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO
Study: NCT06377475

Intervention type: PROCEDURE
Intervention: Questionnaire
Description: The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.

Intervention type: PROCEDURE
Intervention: Questionnaire
Description: The quality of the Michigan-splint will be analyzed according to different interventions (wax or jig jaw relation) and a questionnaire that quantify the occlusal contacts of the splint.
Study: NCT05817643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-984923
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-984923
Description: Oral capsule
Study: NCT05037032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Pill
Description: 50 mg PO one-time only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for naltrexone
Study: NCT06331754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-enabled blood pressure management
Description: The intervention will consist of a technology-enabled remote hypertension management program.
Study: NCT04697472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFT System
Description: The LIFT System delivers the ARC Therapy to improve upper extremity function in individuals with tetraplegia.
Study: NCT05670964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connecting valve system
Description: UPLUG Port (changed every 29 days) and UPLUG Disposable (changed at every dialysis session) ensure the connection between a regular haemodialysis catheter and an extracorporeal circuit, and proceed to different steps of haemodialysis session without handling the Luer-Lock connectors of the haemodialysis catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Central haemodialysis Venous Catheter
Description: Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
Study: NCT04514497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT05919745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Description: Preoperative delivery of ibuprofen per os.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative delivery of placebo per os.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
Study: NCT05325788

Intervention type: OTHER
Group type: OTHER
Intervention: e-Covery
Description: Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.

Intervention type: OTHER
Group type: OTHER
Intervention: e-Covery
Description: Through the e-Covery app, participants will receive place-specific messages, sent when participants pass locations identified as triggers.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator Condition
Description: Through the e-Covery app, participants will receive a single general message sent daily in the morning.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparator Condition
Description: Through the e-Covery app, participants will receive a single general message sent daily in the morning.
Study: NCT04731181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile application (little lovely dentist).
Description: mobile application
Study: NCT05497154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Arm
Description: The training will be composed of 4 separate training sessions provided every 2 - 4 weeks. During the 1st session (45 minutes), the investigators will educate the physical therapist about the different categories of opioid use including opioid misuse (OM) and the risks associated with OM as well as training to engage the patient in a conversation about opioid use. The 2nd and 3rd sessions (30 minutes each) involve training in procedures to screen and assess patients at risk for OM, respectively. The 4th session (30 minutes) involves training in procedures to refer patients to a specialist or a primary care provider for further treatment if OM is suspected.
Study: NCT05427708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure
Description: See: Arm/group descriptions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnometry-Guided Respiratory Intervention
Description: See: Arm/group descriptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Education
Description: See: Arm/group descriptions
Study: NCT05919745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Both groups will be given rescue medication in the form of 1,000 mg tabs of acetaminophen every 6 hours per os as needed for pain (maximum allowed daily dose 4,000 mg per FDA) and will be allowed to receive ibuprofen or other analgesic medication as needed if pain is not controlled by acetaminophen alone. The subjects will receive the rescue medication pills at the end of the surgical appointment.
Study: NCT05139758

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biodex Balane System
Description: The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biodex Balane System
Description: The Biodex balance system will be used for the assessment of static and dynamic balance of all children in the current study.
Study: NCT05080608

Intervention type: OTHER
Intervention: Surgery
Description: Treatment according to clinical practise
Study: NCT05103709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MULTI-FORTIFIED
Description: Treatment with multifortified bread for 120 days
Study: NCT04802967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 300 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules to maintain the blind
Study: NCT05103709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FORTIFIED
Description: Treatment with standard bread, fortified according to current Peruvian guidelines for 120 days
Study: NCT05670964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central haemodialysis Venous Catheter
Description: Central haemodialysis venous catheter (CE marked) will be used within the scope of their intended purpose during the dialysis session
Study: NCT06396507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin Solution
Description: permethrin 5 % solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Solution
Description: permethrin 5 % solution
Study: NCT06047470

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Care
Description: Lactating parents will participate in kangaroo care (holding an infant upright, directly on the chest with skin-to-skin contact) prior to expressing a breast milk sample.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Kangaroo Care
Description: Lactating parents will provide a breast milk sample after having no contact with their infant for at least 6 hours.
Study: NCT06396507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Solution
Description: permethrin 5 % solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin Solution
Description: permethrin 5 % solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur
Description: Sulfur 10%+ vaseline 90 % ointment
Study: NCT06517615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visit Supported Nursing Training Program
Description: Individualized Nurse Education Program with Home Visit Support (• Walking and exercise programs, Disease self-management training for those with chronic diseases, techniques and practices that facilitate medication compliance, vital sign monitoring, • • • Nutrition charts and follow-ups, food characteristics information and weight tracking, cooking activities in the kitchen,• Helping to create family and friend systems, creating neighbor communication mechanisms
Study: NCT04388280

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Functional assessment of coronary artery disease
Study: NCT04768634

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Provocative electrophysiology study
Description: Provocative electrophysiology testing will be performed at the bedside using the temporary pacing wires placed at the time of surgery.
Study: NCT06315998

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography

Intervention type: DEVICE
Intervention: Magnetocardiography
Description: Magnetocardiography
Study: NCT04388280

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT angiography
Description: Anatomical assessment of coronary artery disease
Study: NCT05687695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: backward walking program
Description: six weeks of backward walking program at self selected speed for 30 minutes 3 times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core training
Description: six weeks of core training program including curl up, lateral plank on both sides, bird dog exercises done 3 times per week
Study: NCT05787444

Intervention type: DIAGNOSTIC_TEST
Intervention: LumiraDx SARS-CoV-2 & Flu A/B
Description: The LumiraDx SARS-CoV-2 \& Flu A/B test is an automated rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform, for near-patient testing, intended for the qualitative and differential detection of nucleocapsid viral antigens from SARS-CoV-2, influenza A, and influenza B in an anterior nares sample (from both nostrils) collected by a healthcare professional for individuals aged 2 years and older. The test is authorized for individuals with symptoms of COVID-19, influenza A and B within the first 6 days of symptom onset.
Study: NCT06288672

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: True avoidance diet
Description: Food patch test-directed avoidance diet for 16 weeks where participant avoids avoid eating the food(s) to which they are allergic

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham avoidance diet
Description: Avoidance diet for 16 weeks of randomly selected foods to which the patch testing did not show an allergy